Somatic Test
prev next

TARGT First

Biomaker testing for All at an affordable price
TARGT First is one of the most focused and affordable pan-solid Cancer Gene panels available, with 72 most commonly mutated cancer-associated genes with a high level of evidence for both targeted therapy and prognostication. line
This test covers the most known genomic biomarkers for which NCCN and FDA-approved therapy options are available to treat solid cancers. It is developed to make cancer biomarker testing affordable and accessible for every cancer patient. line
Tumor heterogeneity is a major problem limiting targeted therapies' efficacy and compromising treatment outcomes. An integrated approach to solid and liquid biopsy provides a better understanding of tumor biology and has advanced our knowledge of the molecular landscape of cancer to an unprecedented level. line
Additionally, TARGT First can provide a combined NGS approach using solid & liquid biopsy to gain insights from both the sample sources, thereby mitigating each other’s limitations and aiding in the optimal resolution of the disease genomic landscape. line

SNVs/InDels & CNAs Coverage in TARGT First

ABL1 ALK APC AR ATM BARD1 BMPR1A BRAF BRCA1 BRCA2
BRIP1 CDK12 CDK4 CDK6 CDKN2A CHEK1 CHEK2 CTNNB1 EGFR EPCAM
ERBB2 ERBB3 EZH2 FANCL FGFR1 FGFR2 FGFR3 GAPDH IDH1 IDH2
JAK2 KIT KRAS MAP2K1 MAP2K2 MDM2 MET
(exon 14 skipping)		 MLH1 MLH3 MSH2
MSH6 MUTYH NRAS PALB2 PDGFRA PDGFRB PIK3CA PMS1 PMS2 POLD1
POLE POLH PTEN RAD50 RAD51 RAD51B RAD51C RAD51D RAD54L RB1
RET ROS1 SMAD4 STK11 TP53 TSC1 TSC2
Gene Fusions Coverage in TARGT First

ALK FGFR2 FGFR3 MET
(exon 14 skipping)		 NRG1 NRG2 NTRK1 NTRK2 NTRK3 RET
ROS1

Benefits of TARGT First Gene Panel Testing

Targeted Therapy Guidance

Identifying specific genomic alterations, such as mutations, amplifications, or fusions, helps identify potential therapeutic targets that assist oncologists in selecting the most appropriate targeted therapies for individual patients, increasing the likelihood of treatment success.

Prognostic Information

Certain genetic alterations can influence the prognosis of cancer patients, such as indicating a higher likelihood of disease recurrence or metastasis. This gene panel helps oncologists better understand the patient’s disease trajectory and tailor their management strategies by identifying these prognostic biomarkers.

Cost-Effectiveness

This gene panel is designed to make cancer biomarker testing affordable and accessible for all cancer patients. The test optimizes cost without compromising the essential genes for analysis. This affordability enables a broader population of patients to benefit from genomic profiling and personalized treatment approaches, ultimately improving patient outcomes.

Combined NGS Approach

This gene panel utilizes a combined NGS approach that includes solid and liquid biopsy samples. This approach enhances the resolution of the disease genomic landscape by leveraging the strengths of each sample source.

Why Choose 4baseCare's TARGT First Cancer Gene Panel?

Comprehensive Analysis

Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.

Advanced Technology

We utilize cutting-edge genomic sequencing technologies to deliver precise and detailed genetic information.

Expert Team

Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.

Confidentiality and Privacy

We adhere to strict privacy protocols and maintain the confidentiality of your genetic information.

download
Downloads
book
Book your Test
ct
Compare Our Tests
loader